Form 4: United Therapeutics Director Christopher Patusky Executes Stock Option Exercises and Sales
SEC Form 4 Filing
Director Christopher Patusky of United Therapeutics Corp. executed stock option exercises and sales on September 3rd and 4th, 2024.
Summary
- Christopher Patusky, a director at United Therapeutics Corporation, engaged in transactions involving the company's common stock on September 3rd and 4th, 2024.
- On September 3rd, Patusky exercised options to acquire 700 shares of common stock at a price of $175.43 per share and then sold those 700 shares at a weighted average price of $360.3051.
- Following these transactions on September 3rd, Patusky directly owned 900 shares of common stock.
- On September 4th, Patusky exercised options to acquire 4,300 shares of common stock at $175.43 per share and then sold those 4,300 shares at a weighted average price of $353.3567.
- After the September 4th transactions, Patusky directly owned 900 shares and indirectly owned 1,100 shares through a trust.
- The stock options exercised had an exercise price of $175.43 and were originally granted on June 26, 2016, expiring on June 26, 2025.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Insider trading activity is a common occurrence in publicly listed companies like United Therapeutics.
- Comparing Patusky's transactions to those of other directors in similar biotech firms (e.g., Gilead Sciences, Amgen) would provide context on the scale and frequency of such activities.
- Analyzing the timing of these transactions relative to major company announcements or industry events can offer further insights.
Stakeholder Impact
- Shareholders may view these transactions as part of the director's personal financial management.
- The transactions themselves are unlikely to have a significant impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 06/26/2016 | Date the stock options were granted. |
| 09/03/2024 | Date of first transaction: exercise and sale of 700 shares. |
| 09/04/2024 | Date of second transaction: exercise and sale of 4,300 shares. |
| 06/26/2025 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.